Lucy Day
Director of Finance/CFO bei AN2 THERAPEUTICS, INC.
Vermögen: 99 538 $ am 31.03.2024
Profil
Lucy O.
Day is currently the Chief Financial & Accounting Officer at AN2 Therapeutics, Inc. She also holds the position of Chief Financial Officer at the same company since 2019.
Prior to her current roles, she worked as Vice President at Bank of America Corp.
from 1990 to 1994.
From 1994 to 2002, she served as the Chief Financial Officer at Centaur Pharmaceuticals, Inc. Following that, she held the position of CFO, VP-Human Resources & Finance at Anacor Pharmaceuticals LLC from 2002 to 2016.
Ms. Day completed her undergraduate degree at the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0,10% | 15.03.2024 | 30 627 ( 0,10% ) | 99 538 $ | 31.03.2024 |
Aktive Positionen von Lucy Day
| Unternehmen | Position | Beginn |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Director of Finance/CFO | 01.11.2019 |
Ehemalige bekannte Positionen von Lucy Day
| Unternehmen | Position | Ende |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Director of Finance/CFO | 01.08.2016 |
| Centaur Pharmaceuticals, Inc. | Director of Finance/CFO | 01.01.2002 |
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | 01.01.1994 |
Ausbildung von Lucy Day
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| AN2 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Centaur Pharmaceuticals, Inc. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
